These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 34778045)

  • 1. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
    Li Y; Zhan Z; Yin X; Fu S; Deng X
    Front Oncol; 2021; 11():731535. PubMed ID: 34778045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
    Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapies in Triple-Negative Breast Cancer.
    Marmé F; Schneeweiss A
    Breast Care (Basel); 2015 Jul; 10(3):159-66. PubMed ID: 26557820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in targeted strategies for triple-negative breast cancer.
    Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
    Tong L; Yu X; Wang S; Chen L; Wu Y
    Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
    Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
    Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer.
    Shewale H; Kanugo A
    Curr Pharm Biotechnol; 2024 Jul; ():. PubMed ID: 39092645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target-Oriented Classification of Triple-negative Breast Cancer.
    Mizumoto S; Inubushi S; Miki M; Nakamura H; Baba M; Yamashita Y; Yamamoto M; Inoue S; Tanino H; Kunihisa T
    Anticancer Res; 2023 Nov; 43(11):5067-5072. PubMed ID: 37909966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
    Tazzite A; Jouhadi H; Benider A; Nadifi S
    Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State of art of advanced triple negative breast cancer.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Aparicio Salcedo MI
    Breast J; 2019 Sep; 25(5):967-970. PubMed ID: 31155832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted approaches to triple-negative breast cancer: current practice and future directions.
    Brunello A; Borgato L; Basso U; Lumachi F; Zagonel V
    Curr Med Chem; 2013; 20(5):605-12. PubMed ID: 23278396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly targeted therapies for metastatic triple-negative breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer.
    Varshini MS; Krishnamurthy PT; Reddy RA; Wadhwani A; Chandrashekar VM
    Curr Cancer Drug Targets; 2024 Feb; ():. PubMed ID: 38385495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.
    Zhang Z; Zhang R; Li D
    Biologics; 2023; 17():113-128. PubMed ID: 37767463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
    Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
    Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer: A run-through of features, classification and current therapies.
    Manjunath M; Choudhary B
    Oncol Lett; 2021 Jul; 22(1):512. PubMed ID: 33986872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
    Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
    J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.